Drugs / NRT6003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06310590 | Aug 2023 → Jun 2025 | hepatocellular carcinoma | Chengdu New Radiomedicine Technology Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRT6003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06310590 ↗ |
| Modality | Other / unclassified | “Yttrium-90 carbon microspheres” NCT06310590 ↗ |